Key result
PAPP-A/proMBP complex levels were significantly elevated in acute coronary syndrome, demonstrating high diagnostic accuracy (AUC 0.919) for detecting STEMI in troponin-positive cases.
Why the study?
Does PAPP-A/proMBP complex measurement improve the early detection of acute coronary syndromes compared to cardiac troponin I?
Cross-Sectional (n=283)
No
Does PAPP-A/proMBP complex measurement improve the early detection of acute coronary syndromes compared to cardiac troponin I?
Effect estimate: AUC 0.919 (95% CI 0.849-0.989)
p-value: p=<0.0005
May support PAPP-A/proMBP as adjunct in troponin-positive STEMI; leaves open added value for early ACS detection over troponin.
Kryptor system was proven to be a rapid, standard method for pregnancy-associated plasma protein A and proform eosinophilic major basic protein (PAPP-A/proMBP) complex detection in coronary artery disease (CAD). No age and/or gender differences in 51 controls and 110 stable coronary artery disease (SCAD) patients were found. SCAD patients did not differ from controls and no difference in PAPP-A/proMBP levels with regards to the number of affected vessels was found. In 21 unstable angina pectoris (UAP), in 35 without and 66 with ST elevation acute myocardial infarctions (NSTEMI, STEMI respectively) patients PAPP-A/proMBP levels were increased (P=0.004 and P<0.0005, respectively). PAPP-A/proMBP levels did not correlate with cardiac troponin I (cTnI) in STEMI and NSTEMI patients. PAPP-A/ proMBP increase was more frequent than cTnI (P=0.036) within the early phase of STEMI. In NSTEMI patients PAPP-A/proMBP positivity was present in 50% of cTnI negative cases. Receiver operating characteristic (ROC) analysis revealed the highest diagnostic accuracy of PAPP-A/proMBP (0.919) in STEMI cTnI positive cases. The highest specificity/sensitivity PAPP-A/proMBP levels for particular acute coronary syndrome (ACS) types were 10.65-14.75 mIU/l. Combination of PAPP-A/proMBP with cTnI increases their diagnostic efficacy within the early phase of ACS. Our results suggest that PAPP-A/proMBP complex is involved in processes preceding vulnerable plaque development in ACS.
No takes yet. Share an insight, caveat, or question.
Hájek et al. (2008) conducted a cross-sectional in Coronary Artery Disease (n=283). PAPP-A/proMBP complex levels vs. Controls and stable CAD patients was evaluated on Diagnostic accuracy (Area Under the ROC Curve) of PAPP-A/proMBP for STEMI (cTnI+) vs controls (AUC 0.919, 95% CI 0.849-0.989, p=<0.0005). PAPP-A/proMBP complex levels were significantly elevated in acute coronary syndrome, demonstrating high diagnostic accuracy (AUC 0.919) for detecting STEMI in troponin-positive cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: